East China medicine firepower all open! 7 new drugs Moquan rub palm diabetes product line full layout

Pharmaceutical Network on May 14th as a pharmaceutical industry white horse shares, East China Pharma 2019 operating income and net profit reached a new high, pharmaceutical industry business income for the first time exceeded 10 billion yuanFacing the national medical reform environment, East China Pharma decided to transform the overall innovation, focusing on three major areas in the future, cleaning up low barriers, low-value generic drugsIn 2019, the company invested 1,055 million yuan in research and development expenses, up 49.14% YoY, with key generic drugs entering the golden harvest period and the layout of the whole product line for diabetesMinet data show that East China Medicine in the focus of clinical research innovative drugs and biosimilars there are 7, of which 4 are 1 class of new drugs, Mehuadine, Lilalutide has entered the clinical phase III2015-2020 East China Pharmaceutical Performance (unit: RMB 100 million)Recently, East China Pharma handed over the 2019 "report card": operating income of RMB35.446 billion, up 15.60% YoY; As a pharmaceutical industry white horse shares, East China Pharmaceutical revenue and net profit reached a new high, for 20 consecutive years to maintain solid growth in operating performanceaccording to, East China Pharma was listed on the Shenzhen Stock Exchange in December 1999After more than 20 years of development, the company's business covers the entire pharmaceutical industry chain, to the pharmaceutical industry as the leading, while expanding the pharmaceutical business and medical industry, has developed into a collection of pharmaceutical research and development, production, distribution as one of the large-scale integrated pharmaceutical listed companiesthe growth rate of the main product lines of East China Pharmaceuticalsthe pharmaceutical industry sector, East China Pharma chronic kidney disease, diabetes, transplant ation immune, digestion and other four core pipelines have maintained a good growth trend, operating income exceeded 10 billion yuan for the first time, reaching 10.508 billion yuan, net profit of 2.198 billion yuan, respectively, an increase of 28.02% and 18.14% year-on-yearPharmaceutical business revenue of 25,098 million yuan, to maintain the leading position in Zhejiang Province pharmaceutical business, medical and u.Sindustry continues to open up domestic and foreign markets, the annual revenue exceeded 1.2 billion yuanin the face of medical reform policy in 2019, East China Pharma once again handed over a bright performance answer, in the face of Acapo sugar country's failure of the bid and domestic innovation drug research and development hot 2020, East China Medicine decisive decision-making: comprehensive innovation transformation! By 2025, East China Pharma will transform itself from a traditional generic drug company into a leading innovative pharmaceutical company in China, and in the future, East China Pharma will become a leading multinational pharmaceutical companyIn 2019, the company continued to promote the transformation of research and development, with annual rampons of 1,055 million yuan, up 49.14% YoY, accounting for 10% of the pharmaceutical industry's revenue, and the number of research and development personnel rapidly expanded from 550 to 1078Through independent development, external introduction, project cooperation and other ways to focus on anti-tumor, endocrine and autoimmune three core therapeutic areas of innovative drugs and high-tech barriers to research and development layout;key generic drugs into the golden harvest period, the company is expected to be approved in 2020-2021 the main products are: diabetes drug sigretin metformin tablets, Englili net metformin tablets, cagulion net tablets, liraglutide injections; Tumor drug to crate tablets, anamorphdore tablets, sorafen tablets; super antibiotic carpofin net, mikafen net injection, linazine amine tablets; digestive drug omeprazole sodium bicarbonate capsules; cardiovascular drug macistantatablets, etc the main research and development of generic drugs
meters of net data show that Most of the key products to be approved by East China Pharma sales in the billion yuan level, after the approval of the listing will further boost the company's performance In 2019, China's urban public , county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) end-of-life diabetes drug sales of 57.162 billion yuan, an increase of 11.49 percent year-on-year Among them, Novo Nordisk's liraglutide injection sales were 859 million yuan, up 75.21% YoY, and sales of Sigretin metformin tablets in MersaEast exceeded 100 million yuan, up 21.14% YoY Sales of end-
drugs in China's public medical institutions in 2019 amounted to 96.564 billion yuan, up 21.16% YoY Among them, the sales of tochp tablets amounted to 2.147 billion yuan, sales of anaquate tablets amounted to 1.302 billion yuan, and sales of toluene solafi tablets amounted to 1.325 billion yuan In 2019, China's public medical institutions end-use antifungal drug sales of 10.377 billion yuan, carpofen net sales of 2.230 billion yuan, an increase of 18.53 percent year-on-year focus on the treatment area and market size is of concern, East China combined with market competition pattern and project research and development progress to comprehensively adjust the existing product structure, clean up and eliminate some low barriers, low commercial value of generic drug development, including anti-tumor field of ellotinib tablets, Imatinib tablets, posutinib tablets, super antibiotics in the field of non-damycin tablets and Dabawan frozen powder needle project, digestive tract field of the endobartic powder meter net data show that in 2019 China's public medical institutions terminal Roche's hydrochloric acid Ellotinib tablet sales of 421 million yuan, Shanghai Chongno in September 2019 won the first imitation, Haussen, Xinlitai, Collum and other six the product listing application in the trial Imatinib is a "4 plus 7" variety, generic drugs have been approved by Zhengda Tianqing, Howson, Shi medicine 3, in 2019 in China's public medical institutions terminal sales of 2.662 billion yuan, down 6.24% YoY No companies have submitted listing applications in the domestic market of Posutinib, non-damycin, Dabawanstar, and left-handed paolazole East China Pharmaceutical Focus in the research of new drugs
rice net data show that East China Medicine in the focus of clinical research innovative drugs and biosimilars there are 7, of which 4 for a class of new drugs, Maihuatini, Lilalutide has entered the clinical phase III Myhuatinib is a second-generation EGFR-TKI targeted drug, the treatment of advanced non-small cell lung cancer Phase III clinical trial has been launched, the company strives to use Mehuatinib for the first/second line of rare gene mutation phase II single-arm clinical trial results directly reported to the market TTP273 is an oral GLP-1 innovative drug introduced by East China Pharma, while HD118 is a DPP-4 inhibitor from the company's technology transfer The field of diabetes medicine is the core product line of East China Medicine, the company has formed an innovative target and differentiated generic product pipeline layout at the clinical and important drug targets of diabetes, with key products in GLP-1, DPP-4, SGLT-2, three-generation insulin and single anti-drug Earlier the company with oral preparation Acapo sugar tablets (Cabopin) to occupy the leading position in the domestic diabetes market, in the face of the impact of Acapo sugar collection, the exclusive product Acapo sugar chewing tablets have been included in the 2019 health insurance negotiations directory, the upcoming listing of generic drugs and innovative drugs will also form a relay the transformation of innovative drugs has a long way to go, East China Pharma has formulated a strategic plan for the development of innovative drugs by 2025, and completed no less than 15 innovative varieties (including innovative drugs, improved new drugs, innovative medical products and equipment) each year during the planning period In 2019, more than 15 innovative projects have been established, including HD1902, HD1903 and HD1906 and other types of innovative drugs in the field of tumor and autoimmunity, HD1901, HD1905, HD-IM-001 and other new indications or new dosage type 2 new drugs, further enrich the innovative product pipeline pipeline sources: company annual report, rice net database note: data statistics if there are omissions, welcome to point the right!